Bone Biologics Corporation (BBLG)
0.74
0.05 (7.67%)
At close: Apr 11, 2025, 3:45 PM
0.70
-5.16%
After-hours: Apr 11, 2025, 05:58 PM EDT
7.67% (1D)
| Bid | 0.7 |
| Market Cap | 2.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.32M |
| EPS (ttm) | -4.83 |
| PE Ratio (ttm) | -0.15 |
| Forward PE | -0.5 |
| Analyst | n/a |
| Ask | 0.73 |
| Volume | 93,990 |
| Avg. Volume (20D) | 168,335 |
| Open | 0.68 |
| Previous Close | 0.69 |
| Day's Range | 0.68 - 0.78 |
| 52-Week Range | 0.64 - 4.25 |
| Beta | 1.11 |
About BBLG
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L...
Industry Medical - Devices
Sector Healthcare
IPO Date Oct 13, 2021
Employees 2
Stock Exchange NASDAQ
Ticker Symbol BBLG
Website https://www.bonebiologics.com
8 months ago
+0%
Bone Biologics shares are trading lower after the ...
Unlock content with
Pro Subscription
9 months ago
Bone Biologics shares are trading lower. The company announced that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company's NB1 bone graft device.
8 months ago · businesswire.com
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross ProceedsBURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
